V2V Wins 2025 International Torch Award

Vision2Voice Healthcare Communications is honored to be named one of five winners of the 2025 BBB International Torch Awards for Ethics! V2V has previously been awarded in the USA at the regional level on five previous occasions, but this recognition marks our first on the international stage. For over a decade, the BBB’s Torch Award for Ethics has been the only major award V2V has submitted for because it’s the only award that affirms our commitment to our core values, which have shaped every decision and client relationship.

“We’ve long believed The Torch Award is the most significant recognition Vision2Voice can achieve as an organization. Since our founding, our respect-centered core values have been at the forefront of each complex decision we’ve made as a company,” said Daniel Rehal, President and Founder of V2V. “This Torch Award is validation that our people have created something special by making big commitments, keeping them, and conducting our business the right way.”

Since 1996, these awards have celebrated North American for-profit businesses that uphold ethical practices and foster trust in the marketplace. Thank you to the International Association of Better Business Bureaus (IABBB) and to our employees, clients, stakeholders, and supporters who made this achievement possible!

Recent Posts

Speakers on a Shelf

Your Speaker’s Bureau Has a Shelf Life: Here’s How to Know When It Needs a Refresh

Nobody wants to be the last one to realize the shelf life of their milk has expired. Yet in biopharma marketing, it happens with speaker’s...

Read More
Globe with Pills

What’s Trending in BioPharma – March 2026

Europe risks falling behind in the global BioPharma race, the FDA is working to increase accessibility to personalized treatments in rare diseases, and regulators are...

Read More
Pills scattered on a table with money

What’s Trending in BioPharma – February 2026

The BioPharma industry is in rapid flux, shaped by transforming drug pipelines, the ongoing political battle over lowering drug prices, and a new rebate model...

Read More